Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Mabwell (Shanghai) Bioscience Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2017-05-12

Employees: 1.4K

Market Cap: -

Website: https://www.mabwell.com

Clinical Trials

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 9MW3011
Drug: 9MW3011 placebo

First Posted Date: 2024-04-29

Last Posted Date: 2024-12-27

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT06389942

Locations: 🇨🇳
PKUcare Luzhong Hospital, Zibo, Shandong, China

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Phase 3

Recruiting

Conditions: Advanced Urothelial Carcinoma

Interventions: Drug: 9MW2821
Drug: Chemotherapy

First Posted Date: 2024-01-09

Last Posted Date: 2025-04-13

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 432

Registration Number: NCT06196736

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Phase 1

Active, not recruiting

Conditions: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: 9MW1911
Drug: Placebo

First Posted Date: 2023-12-18

Last Posted Date: 2025-05-20

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT06175351

Locations: 🇨🇳
Baogang Hospital (No 3 Hospital Affiliated to Medical College of Inner Mongolia), Baotou, China
🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳
Peking University Shougang Hospital, Beijing, China

and more 19 locations

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Phase 1

Not yet recruiting

Conditions: Advanced Urothelial Carcinoma

Interventions: Drug: 9MW2821
Drug: Toripalimab

First Posted Date: 2023-10-12

Last Posted Date: 2023-10-12

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT06079112

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: 7MW3711 for injection

First Posted Date: 2023-08-23

Last Posted Date: 2023-09-13

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 281

Registration Number: NCT06008366

Locations: 🇨🇳
Ethics Committee of Fudan University Shanghai Cancer Center, Shanghai, 上海市, China

A Study of 7MW3711 in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: 7MW3711 for injection

First Posted Date: 2023-08-23

Last Posted Date: 2023-09-13

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 164

Registration Number: NCT06008379

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Xuzhou Central Hospital, Xuzhou, Jiangsu, China

and more 2 locations

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: 9MW2921

First Posted Date: 2023-08-14

Last Posted Date: 2024-11-21

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 261

Registration Number: NCT05990452

Locations: 🇨🇳
Fudan University Shanghai Cancer Centel, Shanghai, China

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects

Phase 1

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: 9MW3811 Injection
Drug: Placebo

First Posted Date: 2023-06-22

Last Posted Date: 2023-09-01

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05912049

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Malignant Solid Tumor

Interventions: Drug: 9MW3811 Injection

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-22

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 27

Registration Number: NCT05911984

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

An Evaluation of 9MW1911 Injection in Healthy Subjects

Phase 1

Active, not recruiting

Conditions: Asthma
Atopic Dermatitis
COPD

Interventions: Drug: Experimental drug 9MW1911
Drug: Placebo

First Posted Date: 2023-04-07

Last Posted Date: 2023-04-07

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT05803902

Locations: 🇨🇳
Peking Union Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy